Product Data Sheet

Doxorubicin-¹³C,d₃ TFA

Cat. No.: HY-15142AS1

Molecular Formula: $C_{28}^{13}CH_{27}D_3F_3NO_{13}$

Molecular Weight: 661.55

Target: Antibiotic; Endogenous Metabolite; Isotope-Labeled Compounds

Pathway: Anti-infection; Metabolic Enzyme/Protease; Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	Doxorubicin- 13 C,d $_3$ (TFA) is the deuterium and 13 C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μ M, thus stoppin
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Doxorubicin-13C,d3 (TFA) has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009 May;9(5):338-50.; Rhee HK, et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;1
- [2]. Rhee HK, et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8.
- $[3]. \ John\ L\ Nitiss, et\ al.\ Targeting\ DNA\ topoisomerase\ II\ in\ cancer\ chemotherapy. Nat\ Rev\ Cancer.\ 2009\ May; 9(5):338-50.; Rhee\ HK, and the properties of th$

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA